Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients.


Journal

Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018

Informations de publication

Date de publication:
May 2019
Historique:
pubmed: 29 1 2019
medline: 14 8 2019
entrez: 29 1 2019
Statut: ppublish

Résumé

Direct oral anticoagulants (DOACs) are commonly administered at a level that is lower than that recommended by dose reduction criteria. This raises concern regarding the adequacy of anticoagulation achieved. To evaluate the relationship between inappropriate dosing and DOAC levels. Medical records of atrial fibrillation patients who underwent DOAC level testing during 2013-2017 were reviewed. The primary outcomes were drug levels under and above the expected steady-state range, and in the lowest and highest quartiles. Of 143 patients who underwent DOAC measurements, only 87 (60.8%) received the appropriate dose. Levels under the expected range and in the lowest quartile were found in 11.9% and 15.0% of patients treated with appropriate dosing compared to 21% and 41.5% of patients treated with inappropriately low dose. DOAC levels were above the expected range and in the highest quartile in 23.8% and 32.5% of patients treated with the appropriate dose compared to 7.1% and 9.4% treated with inappropriately low dose. In multivariate analysis, the administration of an appropriate DOAC dose was associated with a lower rate of DOAC in the lowest level (adjusted odds ratio [95% CI] 0.30 (0.12, 0.76), P = 0.011). On the other hand, appropriate dose was associated with drug levels in the highest quartile (odds ratio [95% CI] 3.77 (0.12, 0.76), P = 0.011). Treatment with inappropriately low DOAC dosing compared to appropriate dose is associated with lower DOAC levels. However, among those treated with appropriate dosing, a higher proportion had high DOAC levels above the expected range.

Identifiants

pubmed: 30689152
doi: 10.1007/s11239-019-01815-y
pii: 10.1007/s11239-019-01815-y
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Clinical Trial Journal Article

Langues

eng

Pagination

550-557

Références

N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
Thromb Haemost. 2010 Jun;103(6):1116-27
pubmed: 20352166
Europace. 2010 Oct;12(10):1360-420
pubmed: 20876603
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
Kardiol Pol. 2012;70(1):102-3
pubmed: 22267443
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
S Afr Med J. 2016 Sep 08;106(10):1017-1020
pubmed: 27725023
J Thromb Thrombolysis. 2017 Feb;43(2):149-156
pubmed: 27757787
JAMA Cardiol. 2017 May 1;2(5):566-574
pubmed: 28355459
Europace. 2018 Oct 1;20(10):1577-1583
pubmed: 29186393
J Stroke Cerebrovasc Dis. 2018 Jun;27(6):1546-1551
pubmed: 29395644
J Thromb Haemost. 2018 May;16(5):842-848
pubmed: 29532628
Eur Heart J. 2018 Apr 21;39(16):1330-1393
pubmed: 29562325

Auteurs

Bruria Hirsh Raccah (B)

Department of Cardiology, Hadassah University Hospital, Jerusalem, Israel.
Division of Clinical Pharmacy, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Amihai Rottenstreich (A)

Hematology Department, Hadassah-Hebrew University Medical Center, POB 12000, 91120, Jerusalem, Israel.

Netanel Zacks (N)

Hematology Department, Hadassah-Hebrew University Medical Center, POB 12000, 91120, Jerusalem, Israel.

Ilan Matok (I)

Division of Clinical Pharmacy, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Haim D Danenberg (HD)

Department of Cardiology, Hadassah University Hospital, Jerusalem, Israel.

Arthur Pollak (A)

Department of Cardiology, Hadassah University Hospital, Jerusalem, Israel.

Yosef Kalish (Y)

Hematology Department, Hadassah-Hebrew University Medical Center, POB 12000, 91120, Jerusalem, Israel. ykalish@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH